register

News & Trends - MedTech & Diagnostics

Product defect to hurt uptake of next gen diabetes technology

Health Industry Hub | November 28, 2022 |

MedTech News: Subsidising a next generation technology for diabetes care has meant freedom of choice for patients as well as the freedom from wires and tubes. However, a product defect alert issued by the Therapeutic Goods Administration (TGA) will slow down the uptake of this new medical technology that is set to be added to National Diabetes Services Scheme (NDSS) from 1st December.

Insulet Australia has received reports of problems with the Omnipod DASH Personal Diabetes Manager (PDM). These include battery swelling, fluid leaking from the battery and in rare cases, extreme overheating which may pose a fire hazard. The potential harms are burns, exposure to toxins and delay in a patient’s insulin therapy.

According to the company “Our investigation has determined that the Omnipod DASH PDM is at increased risk if charged to full capacity, particularly if left to charge for extended periods of time (e.g. overnight). Omnipod DASH PDMs in use more than 18 months may have an increased likelihood of this issue occurring.”

Diabetes Australia and the diabetes community advocated for the inclusion of Omnipod DASH on the NDSS in the last couple of years. The Omnipod DASH Insulin Management System uses a tubeless, wearable and waterproof pod that is integrated with a small handheld Personal Diabetes Manager to provide calibrated delivery of insulin over a 72-hour period. The pods are disposable and replaced every three days. Patients have been paying over $400 per month for the pod and touchscreen device and have been looking forward to the NDSS listing.

According to the TGA , Insulet will be implementing a software change to update the PDM to limit the charging capacity to reduce the risk of overcharging. Insulet expects your updated Omnipod DASH PDM to be available by June 2023. Patients do not need to call to receive an updated Omnipod DASH PDM. One will automatically be shipped to them when it is available next year.

The TGA has confirmed that at this time the Omnipod DASH PDMs are not being recalled from the market.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - Pharmaceuticals

Sanofi's departing Country Lead leaves three-decade legacy of strategic, compassionate leadership

Sanofi’s departing Country Lead leaves three-decade legacy of strategic, compassionate leadership

Health Industry Hub | April 17, 2024 |

Pharma News: In a significant development for Sanofi’s local operations, Karen Hood, a seasoned leader with 28 years of invaluable […]

More


Human Resources

AbbVie appoints new HR Director with diverse expertise across healthcare

AbbVie appoints new HR Director with diverse expertise across healthcare

Health Industry Hub | April 17, 2024 |

AbbVie has appointed a new Human Resources Director for Australia and New Zealand. Ally Jonas assumed the role earlier this […]

More


Digital & Innovation

Department of Health hits milestone in digital transformation

Department of Health hits milestone in digital transformation

Health Industry Hub | April 17, 2024 |

Digital & Innovation: The Department of Health and Aged Care has reached the midpoint of its digital transformation journey. While […]

More


News & Trends - Pharmaceuticals

Paradigm-changing outcomes for patients with acute myeloid leukaemia

Paradigm-changing outcomes for patients with acute myeloid leukaemia

Health Industry Hub | April 17, 2024 |

Pharma News: Australian researchers have found a new combination treatment to treat a form of leukaemia that prolongs remission. A […]

More


This content is copyright protected. Please subscribe to gain access.